Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
Clinical Trials
79
Active:4
Completed:25
Trial Phases
5 Phases
Phase 1:29
Phase 2:15
Phase 3:18
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (74 trials with phase data)• Click on a phase to view related trials
Phase 1
29 (39.2%)Phase 3
18 (24.3%)Phase 2
15 (20.3%)Phase 4
8 (10.8%)Not Applicable
4 (5.4%)Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
Not Applicable
Not yet recruiting
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT07040930
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Clinical Study of GenSci134 in Healthy Male Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GenSci134Drug: GenSci134 PlaceboDrug: Recombinant Human Growth Hormone Injection (Norditropin®)
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT07016802
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Real-World Clinical Study for Malignant Tumor-Induced Cachexia
Recruiting
- Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaMulticenter Observational Study
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT07008248
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Study on Bioequivalence of Cabergoline Tablets in Human Body
Not Applicable
Recruiting
- Conditions
- Hyperprolactinemia
- Interventions
- Drug: Cabergoline tablets test formulationDrug: Cabergoline tablets reference formulation
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT07008417
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Phase 3
Completed
- Conditions
- Advanced Prostate Cancer
- Interventions
- Drug: Leuprolide Injectable Emulsion (CAMCEVI®)
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT06984159
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
News
No news found